呼出气一氧化氮测定在哮喘-慢阻肺重叠综合征治疗中的应用价值分析

Analysis of the value of fractional exhaled nitric oxide in the treatment of asthma-coronary overlap syndrome

目的研究呼出气一氧化氮(FeNO)测定在哮喘-慢性阻塞性肺疾病(慢阻肺)重叠综合征(ACOS)治疗中的应用价值。方法100例ACOS患者,均给予注射用胸腺肽α1及布地奈德治疗。分别于治疗前后进行FeNO测定与相关指标[嗜酸粒细胞、免疫球蛋白E、超敏C反应蛋白、第1秒用力呼气容积占预计值百分比(FEV1%pred)]检测,并进行对比。结果ACOS患者治疗后FeNO(26.94±5.13)×10^9mmol/L、嗜酸粒细胞(0.38±0.11)×10^9/L、免疫球蛋白E(204.16±33.74)ng/ml、超敏C反应蛋白(5.83±2.97)mg/L均低于治疗前的(40.41±7.73)×10^9 mmol/L、(1.34±0.52)×10^9/L、(252.06±42.33)ng/ml、(10.93±5.47)mg/L,FEV1%pred(75.94±5.63)%高于治疗前的(56.75±8.13)%,差异具有统计学意义(P<0.05)。结论ACOS患者通过FeNO测定诊断效果确切,且能够对患者病情加以评价,在ACOS治疗效果评估方面起到了显著效果。

Objective To study the application value of fractional exhaled nitric oxide(FeNO)in the treatment of asthma-coronary overlap syndrome.Methods A total of 100 patients with ACOS were treated with thymosinα1 and budesonide.FeNO measurement and related indicators[eosinophils,immunoglobulin E,high-sensitivity C-reactive protein,percentage of predicted value of forced expiratory volume in 1st second(FEV1%pred)]were measured before and after treatment and the results were compared.Results After treatment,FeNO(26.94±5.13)×10^9 mmol/L,eosinophils(0.38±0.11)×10^9/L,immunoglobulin E(204.16±33.74)ng/ml and high-sensitivity C-reactive protein(5.83±2.97)mg/L of ACOS patients were lower than those before treatment(40.41±7.73)×10^9 mmol/L,(1.34±0.52)×10^9/L,(252.06±42.33)ng/ml and(10.93±5.47)mg/L,and FEV1%pred(75.94±5.63)%was higher than that before treatment(56.75±8.13)%.The difference was statistically significant(P<0.05).Conclusion The diagnosis effect of ACOS patients by FeNO measurement is accurate,and the patients’condition can be evaluated,which has a significant effect on the evaluation of ACOS therapeutic effect.